INSULIN GLARGINE MARKET ANALYSIS

High cost of insulin glargine is expected to hamper the growth of the global insulin glargine market. For instance, Lantus (insulin glargine injection) is the prime example of an expensive insulin, averaging around US$ 274 per month. The cost for Lantus subcutaneous solution (100 units/mL) is around US$ 308 for a supply of 10 milliliters. However, the monthly cost of the insulin depends on the dosage prescribed. Introduction of or availability of insulin biosimilars is expected to hinder growth of the insulin glargine market. For instance, biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Furthermore, biosimilar insulins are cheaper as compared to original products.

Market Opportunities: Increase in awareness among people about diabetes management

Diabetes affects millions worldwide and its proper management is crucial. As awareness about diabetes and the importance of managing blood sugar levels rises globally, it presents a major growth opportunity for the Insulin Glargine market. More people are recognizing the need to monitor their glucose and seek treatment options like Glargine to control spikes and maintain healthy levels. This increased awareness has been driven by health initiatives by non-profit organizations like the International Diabetes Federation to educate on diabetes prevention and care.